# Pharmacokinetics and Clinical Effects of Escalating Doses of Clonidine in ICU Patients

> **NCT02466373** · PHASE3 · COMPLETED · sponsor: **Deventer Ziekenhuis** · enrollment: 32 (actual)

## Conditions studied

- Delirium
- Critical Illness

## Interventions

- **DRUG:** Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml

## Key facts

- **NCT ID:** NCT02466373
- **Lead sponsor:** Deventer Ziekenhuis
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2018-04-05
- **Final completion:** 2018-04-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02466373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02466373, "Pharmacokinetics and Clinical Effects of Escalating Doses of Clonidine in ICU Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02466373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*